# Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

> **NCT07720180** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Medical University of South Carolina** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Cancer

## Interventions

- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07720180
- **Lead sponsor:** Medical University of South Carolina
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12-01
- **Primary completion:** 2031-12-01
- **Final completion:** 2032-12-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-07-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07720180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07720180, "Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07720180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*